Securities code: 002584 securities abbreviation: Xilong Scientific Co.Ltd(002584) Announcement No.: 2022-008
Xilong Scientific Co.Ltd(002584)
2021 annual performance forecast
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
(I) performance forecast period
January 1, 2021 - December 31, 2021
(II) performance forecast
\uf0f0 turning losses into profits √ rising in the same direction \uf0f0 falling in the same direction
The current reporting period of the project is the same period of last year
Profit attributable to listed companies: 153 million yuan – 200 million yuan
Profit: 56.8734 million yuan. The net profit of shareholders increased by 169% - 252% over the same period of last year. Profit after deducting non recurring losses: 50 million yuan – 75 million yuan
Profit: 14.189 million yuan. The net profit after profit increased by 252% - 429% over the same period of last year
Basic earnings per share: 0.23 yuan / share – 0.34 yuan / share earnings: 0.1 yuan / share
2、 Communication with accounting firms
The company has made pre communication with the annual report audit accounting firm on matters related to the performance forecast, and there is no difference between the company and the accounting firm on the performance forecast in the reporting period. 3、 Explanation of performance change reasons
1. The change in performance during the reporting period was mainly due to the transfer of part of the equity of Fujian Fujun gene Biotechnology Co., Ltd., the holding subsidiary of the company, and the income obtained was about 105 million yuan, and the non recurring income increased by about 70 million yuan compared with the previous year (Unaudited).
2. During the reporting period, the net profit of the company after deducting non recurring profits and losses increased by 252% - 429% compared with the same period last year, mainly due to the rise in the price of some chemical products due to the influence of market supply and demand and other factors; The company actively seized the market opportunity and the operating revenue increased year-on-year; At the same time, improve the operating efficiency and increase the net profit.
4、 Risk tips
The performance forecast data is the preliminary calculation result of the company's financial department. Without the audit of the accounting firm, there may be differences between the performance forecast data and the 2021 annual report to be disclosed. The specific financial data shall be subject to the 2021 annual report disclosed by the company. Please make careful decisions and pay attention to investment risks.
It is hereby announced
Xilong Scientific Co.Ltd(002584) board of directors January 25, 2022
